Skip to main content
Search
Main content
Graphic representation of data plotted

Webber Lab

Combining state-of-the-art stem cell models with bioinformatics techniques to boost our understanding of the biological mechanisms underlying Parkinson’s disease

Info

UK DRI at Cardiff
Prof Caleb Webber

State-of-the-art modelling of Parkinson’s disease

Approximately 145,000 people in the UK are living with Parkinson’s disease. Its symptoms vary widely from person to person, but often include tremors, stiffness and slow movement. These appear when the brain can’t make enough of a chemical called dopamine and gradually get worse over time as more and more dopamine-producing neurons die.

Although the precise causes of Parkinson’s aren’t fully understood, a complex combination of genetic, lifestyle and environmental factors are involved. Using a relatively new approach called genome-wide association studies, scientists have so far identified a number of genetic variations that can influence risk but don’t guarantee that a person will develop the condition.

The Webber Lab is combining state-of-the-art stem cell models with bioinformatics techniques to boost our understanding of the biological mechanisms underlying Parkinson’s disease. He is aiming to identify new risk genes and investigate how these impact on the function of neurons. The team are also using advanced computational methods to investigate how genetic risk factors can influence varying symptoms presented by patients. They hope to pinpoint key biological pathways that could be targeted with new drugs to prevent or treat Parkinson’s disease– and potentially other diseases with overlapping molecular causes.

Prof Caleb Webber

Prof Caleb Webber is a Group Leader at the UK DRI at Cardiff, and the UK DRI Director of Data Science. Find out more about his career and expertise on his profile page.

Caleb Webber

Research summary

Modelling Parkinson’s disease

This UK DRI programme from Prof Caleb Webber is focused on Parkinson’s disease (PD) and split into three key work streams:

(1) Pseudotemporal modelling of disease mechanisms.

Revealing the causal chain of events behind disease-associated variation can yield key insights and offer multiple opportunities to therapeutically intervene. The Webber Lab are applying state-of-the-art single cell pseudotemporal approaches to stem cell models carrying PD-implicated mutations in the genes, SNCA and GBA. The long-term goal is to identify the causal networks and pathways that lead from genetic or environmental insult through to face-valid cellular phenotypes. Their immediate objectives for this stream are to create an iPSC reporter line (LMX1a) that will enable the sorting of neurons without prior fixing, removing heterogeneity from downstream experiments without limiting their study.

(2) Identifying new disease risk genes.

The team is analysing PD genome wide association (GWA) risk loci to identify genes that underlie the risk in these regions. They have made progress in the informatic prioritisation of these genes and will begin rapid modulation of these genes once the LMX1a-reporter line is in place. The long-term objectives of identifying risk mechanisms will involve generating cell-type specific chromatin accessibility maps in iPSC models and nigral brain tissue, and then combining this with fine mapping and CRISPR to identify the risk-modulating genetic variants and their target genes.

(3) Understanding patient-phenotypic heterogeneity.

The team’s new multiple phenotype mixed model approach has identified three axes of variation which have now been re-identified (replicated) in all three deeply-phenotyped PD cohorts in the world. The first two axes alone account for 75% of all clinical observations, and the quantitative traits these axes provide have identified an overlap between the genetic influences of coronary artery disease and Axis 1, and schizophrenia and Axis 2.

Prof Webber’s current research goal is to extend the approach to the longitudinal data, which is already looking very promising. This work is delivering the underlying nature of PD patient phenotypic variation, providing new routes into the influencing biology, and new opportunities to intervene, most rapidly by enabling import of knowledge through shared risk. Furthermore, identifying how PD patients vary is enabling them to devise how deeply-phenotyped cohorts are best phenotyped.

Key publications

Cell Stem Cell
Published

Single-Cell Sequencing of iPSC-Dopamine Neurons Reconstructs Disease Progression and Identifies HDAC4 as a Regulator of Parkinson Cell Phenotypes.

Authors
Charmaine Lang, Kieran R Campbell, Brent J Ryan, Phillippa Carling, Moustafa Attar, Jane Vowles, Olga V Perestenko, Rory Bowden, Fahd Baig, Meike Kasten, Michele T Hu, Sally A Cowley, Caleb Webber, Richard Wade-Martins
Single-Cell Sequencing of iPSC-Dopamine Neurons Reconstructs Disease Progression and Identifies HDAC4 as a Regulator of Parkinson Cell Phenotypes.
Stem Cell Reports
Published

Reproducibility of Molecular Phenotypes after Long-Term Differentiation to Human iPSC-Derived Neurons: A Multi-Site Omics Study.

Authors
Viola Volpato, James Smith, Cynthia Sandor, Janina S Ried, Anna Baud, Adam Handel, Sarah E Newey, Frank Wessely, Moustafa Attar, Emma Whiteley, Satyan Chintawar, An Verheyen, Thomas Barta, Majlinda Lako, Lyle Armstrong, Caroline Muschet, Anna Artati, Carlo Cusulin, Klaus Christensen, Christoph Patsch, Eshita Sharma, Jerome Nicod, Philip Brownjohn, Victoria Stubbs, Wendy E Heywood, Paul Gissen, Roberta De Filippis, Katharina Janssen, Peter Reinhardt, Jerzy Adamski, Ines Royaux, Pieter J Peeters, Georg C Terstappen, Martin Graf, Frederick J Livesey, Colin J Akerman, Kevin Mills, Rory Bowden, George Nicholson, Caleb Webber, M Zameel Cader, Viktor Lakics
Reproducibility of Molecular Phenotypes after Long-Term Differentiation to Human iPSC-Derived Neurons: A Multi-Site Omics Study.
Hum Mol Genet
Published

Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease.

Authors
Cynthia Sandor, Paul Robertson, Charmaine Lang, Andreas Heger, Heather Booth, Jane Vowles, Lorna Witty, Rory Bowden, Michele Hu, Sally A Cowley, Richard Wade-Martins, Caleb Webber
Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease.

Vacancies

There are currently no vacancies available.

Lab members

  • Dr Viola Volpato (Postdoctoral Researcher)
  • Dr Emeka Uzochukwu (Postdoctoral Researcher)
  • Dr Mateus Bernardo Harrington (Postdoctoral Researcher)
  • Dr Jimena Monzon Sandoval (Staff Scientist)
  • Dr Samuel Neaves (Research Associate)
  • Dr Preethi Sheshadri (Research Associate)
  • Brier Rigby Dames (PhD Student)
  • Suppalek Lewis (Technician)

Collaborators

Lab funders

Thank you to all those who support the Webber Lab!